Axa
OCUL icon

Axa’s Ocular Therapeutix OCUL Stock Holding History

Axa’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-516,500
Closed -$4.79M – 734
2025
Q2 		$4.79M Sell
516,500
-43,019
-8% -$337K 0.01% 574
2025
Q1 		$4.1M Sell
559,519
-78,313
-12% -$602K 0.01% 590
2024
Q4 		$5.45M Sell
637,832
-1,015
-0.2% -$9.9K 0.02% 521
2024
Q3 		$5.56M Buy
638,847
+182
+0% +$1.5K 0.02% 521
2024
Q2 		$4.37M Buy
638,665
+360
+0.1% +$2.22K 0.01% 562
2024
Q1 		$5.81M Buy
638,305
+179
+0% +$1.27K 0.02% 521
2023
Q4 		$2.85M Sell
638,126
-1,108
-0.2% -$3.28K 0.01% 671
2023
Q3 		$2.01M Buy
639,234
+164,334
+35% +$672K 0.01% 710
2023
Q2 		$2.45M Buy
+474,900
New +$2.82M 0.01% 680

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Axa's OCUL Position: Q3 2025 in Review

Axa sold out of Ocular Therapeutix (OCUL) in Q3 2025, closing a stake of 516,500 shares — an estimated $4.79M sold.

Axa first reported a position in OCUL in Q2 2023 and held it in 9 quarters. The position peaked at $5.81M in Q1 2024. 216 funds tracked by Wall St. Rank hold OCUL as of Q3 2025.

  • Axa reported no remaining Ocular Therapeutix position as of Q3 2025 after selling out during the quarter.
  • Axa sold 516,500 Ocular Therapeutix shares in Q3 2025, an estimated $4.79M.
  • Axa first reported a position in Ocular Therapeutix in Q2 2023 and held it in 9 quarters.
  • Axa's Ocular Therapeutix position peaked at $5.81M in Q1 2024.
  • 216 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q3 2025.

Based on Axa's 13F filing for Q3 2025, filed 14 Nov 2025.